1Q EARNINGS: AbbVie buoyed by Humira, touts hepatitis C program
This article was originally published in Scrip
A 17.5% jump in Humira (adalimumab) sales to $2.6bn in the first quarter kept AbbVie's net product sales in positive territory as therapies for controlling cholesterol plunged due to generic competition, putting greater emphasis on the company's future in hepatitis C.
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.